Exhibit
31.2





Provectus
Pharmaceuticals, Inc.


Certification
Pursuant to Rule 13a-14(a)


Section
302 Certification





I, Peter R. Culpepper, the Chief
Financial Officer of Provectus Pharmaceuticals, Inc., certify that:





1.   I  have  reviewed  this  annual  report  on  Form  10-K  of  Provectus
Pharmaceuticals, Inc.;





2.   Based
on my knowledge, this report does not contain any untrue statement of a
material  fact or omit to state
a  material  fact  necessary  to make
the statements made, in light of the circumstances  under which such
statements were
made,  not  misleading  with  respect  to
the  period  covered by this report;





3.   Based
on
my  knowledge,  the  financial  statements,  and  other  financial
information  included  in  this  report,  fairly  present  in
all  material respects the
financial  condition,  results of operations and cash flows
of the smaller reporting company as of, and for,  the
periods  presented in this report;





4.   The  smaller
reporting company
's  other  certifying   officer(s)  and  I  are
responsible  for  establishing  and  maintaining  disclosure  controls  and
procedures  (as defined in Exchange Act Rules  13a-15(e) and
15d-15(e)) and internal control over financial  reporting (as defined
in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the smaller reporting company
and have:





a)   Designed  such  disclosure  controls  and  procedures,  or
caused such
disclosure   controls  and   procedures  to  be  designed   under  our
supervision, to ensure that material information relating to the smaller
reporting company,  including
its  consolidated  subsidiaries,  is made known to
us by others within those entities,  particularly  during
the period in which this report is being prepared;





b)   Designed
such internal  control
over  financial  reporting,  or caused such
internal  control over  financial  reporting to be
designed under
our  supervision,   to  provide  reasonable  assurance  regarding  the
reliability  of financial  reporting and
the  preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;





c)   Evaluated
the effectiveness of the smaller reporting company's  disclosure
controls and procedures  and presented in this report
our  conclusions about the effectiveness of the disclosure controls
and procedures,  as of the  end of
the  period  covered  by  this  report  based  on  such
evaluation;





d)   Disclosed  in
this  report any change in the smaller reporting company 's
internal  control over financial  reporting  that
occurred  during the smaller reporting company's most recent fiscal
quarter that has materially affected,  or
is  reasonably  likely to
materially  affect,  the smaller reporting company's
internal control over financial reporting; and





5.   The
smaller reporting company's other certifying officers and I have disclosed,
based on our most recent  evaluation  of
internal  control  over  financial
reporting,  to the smaller reporting company's auditors and the audit
committee of the smaller reporting company's board of directors (or persons
performing equivalent functions):





a)   All
significant  deficiencies and material weaknesses in the design or
operation  of
internal  control  over  financial  reporting  which
are reasonably  likely to  adversely  affect the
smaller reporting company 's ability to  record, process, summarize
and report financial information; and





b)   Any
fraud, whether or not material, that involves management or other employees who
have a significant role in the smaller reporting company’s internal control over
financial reporting.






Date: 
      March 31, 2010
              By:
              /s/ Peter
      R. CulpepperPeter
      R. CulpepperChief
      Financial OfficerChief
      Operating Officer